Login to Your Account



Clinic Roundup


Tuesday, July 5, 2011
Nuvo Research Inc., of Mississauga, Ontario, said a Phase II trial of Pennsaid Viscous Solution 2 percent (topical diclofenac sodium viscous solution) met its primary endpoint of reducing osteoarthritis pain compared to placebo (p = 0.042).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription